|
|||||
|
|
Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy |
|
| Authors: | Matteo Perrino MD Tommaso De Pas MD Silvia Bozzarelli MD Laura Giordano SD Fabio De Vincenzo MD Fabio Conforti MD Nunzio Digiacomo MD Nadia Cordua MD Federica D'Antonio MD Federica Borea MD Armando Santoro MD Paolo Andrea Zucali MD |
| Affiliation: | 1. Department of Oncology, IRCCS, Humanitas Research Hospital, Milan, Italy;2. Department of Oncology, IRCCS, European Institute of Oncology, Milan, Italy;3. Biostatistic Unit, IRCCS, Humanitas Research Hospital, Milan, Italy;4. Department of Biomedical Sciences, Humanitas University, Milan, Italy;5. Department of Oncology, IRCCS, Humanitas Research Hospital, Milan, Italy Department of Biomedical Sciences, Humanitas University, Milan, Italy |
| Abstract: | |
| Keywords: | activity phase 2 trial regorafenib thymic epithelial tumors toxicity profile |